Smoking modulates neuroendocrine responses to ipsapirone in patients with panic disorder

Neuropsychopharmacology

Volumn 27, Issue 2, 2002, Pages 270-278

  Broocks, A ^a   Bandelow, B ^a,b   Koch, K ^a,b   Bartmann, U ^a,b   Kinkelbur, J ^a,b   Schweiger, U ^a,b   Hohagen, F ^a,b   Hajak, G ^a,b  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Ipsapirone; Nicotine; Panic disorder; Serotonin; Smoking

Indexed keywords

HYDROCORTISONE; IPSAPIRONE;

ADULT; ARTICLE; BODY TEMPERATURE; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; MALE; NEUROBIOLOGY; NEUROENDOCRINE SYSTEM; PANIC; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; SMOKING CESSATION; SYMPTOM;

ADULT; AGORAPHOBIA; BEHAVIOR; BODY TEMPERATURE; BRAIN; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROCORTISONE; MALE; NEUROSECRETORY SYSTEMS; NICOTINE; PANIC DISORDER; PYRIMIDINES; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN; SEROTONIN AGONISTS; SMOKING; SYNAPSES; UP-REGULATION;

EID: 0036298043     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(02)00298-1     Document Type: Article

References (67)

1. Hypothalamic-pituitary-adrenal axis activity in panic disorder: Prediction of long-term outcome by pretreatment cortisol levels
2. Influence of nicotine on the release of monoamines in the brain
3. Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale
4. Urinary excretion of cortisol, norepinephrine, testosterone, and melatonin in panic disorder
5. Salivary cortisol in panic attacks
6. Diurnal variation of cortisol in panic disorder
7. Smoking-associated changes in the serotonergic systems of discrete regions of human brain
8. Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine-II. Effects of acute administration of 1-PP and long-term administration of tandospirone on noradrenergic neurotransmission
9. Psychoimmunoendocrine aspects of panic disorder
10. Vulnerability to psychopathology in nicotine-dependent smokers: An epidemiologic study of young adults
11. Smoking and panic attacks: An epidemiologic investigation
12. Major depression and stages of smoking. A longitudinal investigation
13. Increased psychological responses and divergent neuroendocrine responses to m-CPP and ipsapirone in patients with panic disorder
14. Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder
15. Decreased neuroendocrine responses to meta-chlorophenylpiperazine (m-CPP) but normal responses to ipsapirone in marathon runners
16. Endocrine and physiological changes during "spontaneous" panic attacks
17. Systemic hormonal and physiological abnormalities in anxiety disorders
18. Neurobiological mechanisms of panic anxiety: Biochemical and behavioral correlates of yohimbine-induced panic attacks
19. Serotonin function in anxiety, II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects
20. The dorsal raphe nucleus is a crucial structure mediating nicotine's anxiolytic effects and the development of tolerance and withdrawal responses
21. Psychopharmacology of 5-HT(1A) receptors
22. Comparative effects of serotonergic agonists with varying efficacy at the 5-HT(1A) receptor on core body temperature: Modification by the selective 5-HT(1A) receptor antagonist WAY 100635
23. Measurement of lactate-induced panic and anxiety
24. Paradoxical tranquilizing and emotion-reducing effects of nicotine
25. Cigarette smoking: Implications for psychiatric illness
26. The hypothalamic-pituitary-adrenal system in panic disorder
27. Effects of the novel anxiolytics gepirone, buspirone and ipsapirone on free feeding and feeding induced by 8-OH-DPAT
28. Diagnosis and rating of anxiety
29. Salivary cortisol and behavior: An overview
30. Cortisol and sodium lactate-induced panic
31. Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder
32. Effects of ipsapirone in healthy subjects: A dose-response study
33. M-Chlorophenylpiperazine as a probe of serotonergic function
34. Behavioral indications for serotonin receptor hypersensitivity in panic disorder
35. Smoking and major depression. A causal analysis
36. Nicotine regulates 5-HT(1A) receptor gene expression in the cerebral cortex and dorsal hippocampus
37. 'Normal' cigarette smoking increases free cortisol in habitual smokers
38. 5-HT1A receptor function in depression: Effect of chronic amitriptyline treatment
39. 5-Hydroxytryptamine1A receptor responsivity in obsessive-compulsive disorder. Comparison of patients and controls
40. 5-HT1A receptor responsivity in unipolar depression. Evaluation of ipsapirone-induced ACTH and cortisol secretion in patients and controls
41. Pharmacology of the hypothermic response to 5-HT1A receptor activation in humans
42. Endocrine responses to 5-hydroxytryptamine-1A receptor activation by ipsapirone in humans
43. Corticotropin and cortisol secretion after central 5-hydroxytryptamine-1A (5-HT1A) receptor activation: Effects of 5-HT receptor and beta-adrenoceptor antagonists
44. 5-HT1A receptor-effector system responsivity in panic disorder
45. Lactate provocation of panic attacks, II. Biochemical and physiological findings
46. Nicotine dependence and withdrawal in alcoholic and nonalcoholic ever-smokers
47. Nicotine stimulation of dorsal raphe neurons: Effects on laterodorsal and pedunculopontine neurons
48. Kinetics, brain uptake, and receptor binding of tandospirone and its metabolite 1-(2-pyrimidinyl)-piperazine
49. Comorbid cigarette and alcohol addiction: Epidemiology and treatment
50. Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers
51. Adrenergic function in patients with panic anxiety
52. Neuroendocrine, physiologic, and behavioral responses following intravenous nicotine in nonsmoking healthy volunteers and in patients with Alzheimer's disease
53. Clinical Global Impressions
54. Involvement of 5-HT1A and 5-HT1B receptors for citalopram-induced hypothermia in the rat
55. Development of depression during placebo-controlled trials of bupropion for smoking cessation: Case reports
56. Selective interaction of novel anxiolytics with 5-hydroxytryptamine1A receptors
57. Stimulation of corticosterone secretion by the selective 5-HT1A receptor agonist 8-hydroxy- 2-(di-n-propylamino)tetralin (8-OH-DPAT) in the rat
58. Serotonin-1A antagonists attenuate the effects of nicotine withdrawal on the auditory startle response
59. Beneficial effects of nicotine: Fact or fiction?
60. The corticotropin-releasing hormone stimulation test in patients with panic disorder
61. Increasing diagnosis of nicotine dependence in adolescent mental health patients
62. Nicotine-induced limbic cortical activation in the human brain: A functional MRI study
63. Development of major depression after treatment for smoking cessation
64. Sympathetic nervous system activity in panic disorder
65. Carbon dioxide-induced anxiety. Behavioral, physiologic, and biochemical effects of carbon dioxide in patients with panic disorders and healthy subjects